Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of oncology and infectious diseases. Their lead program is Endoxifen, which is a metabolite of tamoxifen currently in Phase II clinical trials to treat and prevent breast cancer. Atossa is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. The company has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer.

Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. In January 2020, the company changed its name from Atossa Genetics Inc. Atossa Therapeutics is a publicly traded company on the NASDAQ stock exchange under the ticker symbol ATOS. The company has a network of strategic collaborations with leading universities, medical centers, foundations and pharmaceutical partners across the United States, Europe, and the Middle East.

Atossa’s corporate mission is to develop and commercialize innovative therapeutics that improve the lives of patients with cancer and infectious diseases. The company is currently focusing on research and clinical trials for their lead programs and actively exploring new opportunities in their related fields. The company’s products are designed to be cost effective and available to patients in need. Atossa Therapeutics is committed to providing its stakeholders with high-quality products and services that will make a positive impact on the lives of patients.